[
    [
        {
            "time": "",
            "original_text": "[强于大市评级]医药生物行业投资策略：年报密集期 精选业绩预期强烈估值合理的细分龙头",
            "features": {
                "keywords": [
                    "医药生物",
                    "投资策略",
                    "年报",
                    "业绩预期",
                    "估值合理",
                    "细分龙头"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药生物"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "[强于大市评级]医药生物行业投资策略：年报密集期 精选业绩预期强烈估值合理的细分龙头",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 5,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "[推荐评级]医药行业2018年3月份投资月报：创新药2.0+细分市场龙头",
            "features": {
                "keywords": [
                    "医药行业",
                    "投资月报",
                    "创新药",
                    "细分市场",
                    "龙头"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "[推荐评级]医药行业2018年3月份投资月报：创新药2.0+细分市场龙头",
                "Correlation": 7,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 4,
                "Market_Scope": 9,
                "Time_Proximity": 4,
                "Headline_Structure": 8,
                "Source_Recency": 3
            }
        },
        {
            "time": "",
            "original_text": "贝达药业业绩快报点评:降价因素逐步消化,看好长期成长性",
            "features": {
                "keywords": [
                    "贝达药业",
                    "业绩快报",
                    "降价因素",
                    "长期成长性"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "贝达药业业绩快报点评:降价因素逐步消化,看好长期成长性",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        }
    ]
]